🔗 Share this article

A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Treatment Acquiring Traction Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Followers are encouraged to message these profiles privately for supplier links, while also obtaining discount codes.

Active Trade on Messaging Platforms

Separately, a robust trade exists on messaging services, where communities with thousands of members share “before and after” photos, injection guides and claims of rapid British shipping. Vendors promote the drug there before redirecting buyers to other platforms for transactions.

Understanding Retatrutide

This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Experts Express Concerns

However, physicians and pharmacists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is worrisome and could lead to individuals administering substances of uncertain source.

Some professionals said the popularity for the experimental drug could be linked to the rising cost of approved weight loss treatments such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that cannot be marketed or distributed for personal consumption under the British medical regulations.

Some content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still breach pharmaceutical, advertising, and customer laws, risking fines, prosecution or imprisonment.

Service Reaction and Content Elimination

Based on TikTok, the platform has removed problematic content and banned associated keywords and query recommendations. The company said it was committed to keeping the platform safe and allocating resources in strengthening compliance measures.

Digital Marketplace Operations

Research also found groups with up to nine thousand members selling retatrutide using the platform's built-in search feature, which functions like a online catalog. Typing “retatrutide” instantly displays groups with thousands of members, populated with images of weight loss, glowing reviews and step-by-step instructions for preparing or injecting at home.

Within moments of joining one community, a seller posted WhatsApp details, where most transactions occur. The vendor sent an guidebook and guaranteed delivery within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None inquired about weight, medical conditions or previous experience.

Product Details and Pricing

Inside these groups, messages display dark colored parcels with postal service labels, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with purified liquid, or ready-to-use injectors typically priced at £160 for 20mg. When questioned how much time a pen should be used, vendors give contradictory responses ranging from a few weeks to “depends on your body”.

Platform Oversight and Security Measures

A spokesperson for Telegram said it regularly moderated harmful material on its platform including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they can’t verify. Even if the research behind retatrutide is valid, these digital versions may not include what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor connected the increase in interest to current price rises for authorized slimming medications such as Mounjaro. “With costs rising, patients are turning to online platforms. But fake treatments are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her staff has previously seen patients injured by personal administration from unverified sources. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your health,” stated the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Statement

A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any government authority globally. “Therefore at this point no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a company investigational product not yet approved … may expose patients to potentially serious health risks”.